136 related articles for article (PubMed ID: 11849778)
21. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Speleman L; Kerrebijn JD; Look MP; Meeuwis CA; Foekens JA; Berns EM
Head Neck; 2007 Apr; 29(4):341-50. PubMed ID: 17163465
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
Chambers SK; Ivins CM; Carcangiu ML
Int J Cancer; 1998 Oct; 79(5):449-54. PubMed ID: 9761111
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors.
Kono S; Rao JS; Bruner JM; Sawaya R
J Neuropathol Exp Neurol; 1994 May; 53(3):256-62. PubMed ID: 8176408
[TBL] [Abstract][Full Text] [Related]
25. [Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].
Mayerhofer K; Stolzlechner J; Yildiz S; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeillinger R; Speiser P
Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):23-7. PubMed ID: 8852782
[TBL] [Abstract][Full Text] [Related]
26. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
27. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.
Thorarinsdottir HK; Santi M; McCarter R; Rushing EJ; Cornelison R; Jales A; MacDonald TJ
Clin Cancer Res; 2008 Jun; 14(11):3386-94. PubMed ID: 18519768
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.
Bredel M; Pollack IF; Hamilton RL; James CD
Clin Cancer Res; 1999 Jul; 5(7):1786-92. PubMed ID: 10430083
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation.
Zhu A; Shaeffer J; Leslie S; Kolm P; El-Mahdi AM
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):809-15. PubMed ID: 8598357
[TBL] [Abstract][Full Text] [Related]
32. Epidermal Growth Factor Receptor and Ki-67 Expression in Canine Gliomas.
Fraser AR; Bacci B; le Chevoir MA; Long SN
Vet Pathol; 2016 Nov; 53(6):1131-1137. PubMed ID: 27154542
[TBL] [Abstract][Full Text] [Related]
33. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
[TBL] [Abstract][Full Text] [Related]
34. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
35. Volumetric Analysis of Extent of Resection, Survival, and Surgical Outcomes for Insular Gliomas.
Eseonu CI; ReFaey K; Garcia O; Raghuraman G; Quinones-Hinojosa A
World Neurosurg; 2017 Jul; 103():265-274. PubMed ID: 28408263
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N; Kates RE; Schmitt M
J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
[TBL] [Abstract][Full Text] [Related]
37. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
Offersen BV; Riisbro R; Knoop A; Brünner N; Overgaard J;
Acta Oncol; 2007; 46(6):782-91. PubMed ID: 17653901
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor expression in human gliomas.
Torp SH; Helseth E; Dalen A; Unsgaard G
Cancer Immunol Immunother; 1991; 33(1):61-4. PubMed ID: 2021959
[TBL] [Abstract][Full Text] [Related]
39. Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas.
Zhao LL; Xu KL; Wang SW; Hu BL; Chen LR
Histopathology; 2012 Oct; 61(4):726-36. PubMed ID: 22978472
[TBL] [Abstract][Full Text] [Related]
40. PinX1 is up-regulated and associated with poor patients' survival in gliomas.
Bai J; Chen YS; Mei PJ; Liu QH; Du Y; Zheng JN
Int J Clin Exp Pathol; 2015; 8(6):6952-9. PubMed ID: 26261583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
